ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.330
-0.010 (-0.43%)
At close: Aug 28, 2025, 4:00 PM
2.340
+0.010 (0.43%)
After-hours: Aug 28, 2025, 7:57 PM EDT
ImmunityBio Revenue
ImmunityBio had revenue of $26.43M in the quarter ending June 30, 2025, with 2,423.88% growth. This brings the company's revenue in the last twelve months to $56.60M, up 4,227.22% year-over-year. In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth.
Revenue (ttm)
$56.60M
Revenue Growth
+4,227.22%
P/S Ratio
32.78
Revenue / Employee
$83,235
Employees
680
Market Cap
2.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.75M | 14.12M | 2,270.58% |
| Dec 31, 2023 | 622.00K | 382.00K | 159.17% |
| Dec 31, 2022 | 240.00K | -694.00K | -74.30% |
| Dec 31, 2021 | 934.00K | 329.00K | 54.38% |
| Dec 31, 2020 | 605.00K | -1.60M | -72.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IBRX News
- 2 days ago - Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device - Business Wire
- 9 days ago - ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - Business Wire
- 15 days ago - ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy - Business Wire
- 17 days ago - ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - Business Wire
- 23 days ago - ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code - Business Wire
- 4 weeks ago - ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors - Business Wire
- 4 weeks ago - ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - Business Wire
- 5 weeks ago - ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval - Seeking Alpha